Six poster presentations showcase Zymeworks’ next-generation ADC programs, including multiple first-in-class pan-RAS ...

Orum's New Preclinical Data at AACR 2026 on ORM-1153 Highlights Broad Activity in AML and the Potential for Improved Efficacy ...

Six poster presentations showcase Zymeworks' next-generation ADC programs, including multiple first-in-class pan-RAS inhibitor ADCs Data highlight efficacy, tumor-selective delivery, and favorable tol ...

Posters highlight antigen-independent delivery, differentiated efficacy and broad payload versatility of ultra pH-sensitive ...

Zai Lab Limited (NASDAQ:ZLAB) shares rose 2.6% following the release of clinical trial data for its antibody-drug conjugate targeting DLL3 protein. The company re ...

Byondis B.V., an independent biopharmaceutical company creating innovative targeted medicines for patients with cancer, will profile the Company’s first-in-class antifolate and phosphonate ...

Following the presentation on April 19, 2026 from 2:00–5:00 PM PT, the poster titled “PLK1 inhibitor onvansertib potentiates the antitumor efficacy of trastuzumab deruxtecan (T-DXd) and reverses its ...

Indian CDMO Piramal Pharma (NSE: PPLPHARMA) has entered a strategic collaboration with Japan’s Ajinomoto Bio-Pharma Services ...

The inducement stock option has an exercise price of $1.68 per share, which is equal to the closing price of a share of ALX Oncology common stock on the grant date, and vests as follows: 25% of the ...

TheFly reported on April 10 that B. Riley raised its rating on MGNX to Buy from Neutral and assigned a $9 price target.

Interna’s MNM molecules will be integrated with targeting approaches for enhancing functional activity.

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...